SHH Healthcare Drug Manufacturers - Specialty & Generic 600196.SS

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

$ 21.79 0.97 %

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a prominent entity in the pharmaceutical sector, engaged in the research, production, and marketing of medicinal products. Its operations extend across Mainland China and into international territories. The company's multifaceted business structure is divided into five core divisions: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, and Other Business activities. Fosun's pharmaceutical offerings are primarily directed towards therapeutic solutions for oncology, immune system disorders, metabolic diseases, digestive health, and central nervous system conditions. Beyond drug development, the firm also supplies medical equipment and diagnostic instruments. Furthermore, it provides healthcare services, encompassing the management of hospitals. The company's comprehensive scope also includes the wholesale and retail distribution of medicines. Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is headquartered in Shanghai, China.

CEO: Yi Liu - https://www.fosunpharma.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

-

Recommandation

-

DCF

$ 113.08

Loading data...

600196.SS vs S&P500

Loading data...

No data available.

Quick ratio

0.76

indicates that the company may have difficulty covering its short-term debts with its readily available assets.

P/E ratio

16.63

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

1.31

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

7.19 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

3.15 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

4.78

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.81

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

0.58

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

39.78 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
7 indicates good financial health
Altman score
1.37 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.36 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.32 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.